Share |

Content about Medicine

August 25, 2011

No one knows more about wasteful spending than the government, and healthcare is on top of most people’s list when it comes to wasteful spending. Since 2009 the focus has shifted towards bringing down the cost of healthcare spending.

August 24, 2011

One of the largest and most profitable biotechnology companies in the Mid-Atlantic is trying to increase its revenue by developing an oral form of treatment for pulmonary arterial hypertension (PAH).

Silver Spring-based United Therapeutics Corporation (NASDAQ: UTHR) released its FREEDOM-C(2) Phase 3 clinical trial results today but the company announced that the study did not meet its primary endpoint.

August 17, 2011

Rockville-based Emergent BioSolutions Inc. (NYSE:EBS) has started Phase 1b/2 clinical trials study for a new drug that it hopes will aid patients in the treatment of lymphoma.

The treatment labeled TRU-016, will be administered in combination with Rituximab and Bendamustine in patients who have relapsed from indolent B-cellLymphoma.

August 16, 2011

Rockville-based Nabi Biopharmaceuticals (Nasdaq:NABI) has added to its cash stockpile by obtaining $5 Million in milestone payments from Fresenius USA Manufacturing, Inc.

August 12, 2011

Bethesda-based Northwest Biotherapeutics (OTC: NWBO) released a statement to give surety to Investors that its DCVax drug, will not run into the same issues currently facing Seattle, Washington-based, Dendreon Corporation's (NASDAQ:DNDN) Provenge immune therapy drug.

August 11, 2011

Two Rockville-based firms involved in drug development have teamed up to develop a new Tuberculosis (TB) vaccine.

Aeras a non-profit focused on developing vaccines to prevent TB and Emergent BioSolutions a biotechnology firm mostly known for its Antrax drug--BioThrax--are now entering a Phase IIb Proof-of-Concept Trial of Emergent's Modified Vaccinia virus Ankara--Antigen 85Abased TB vaccine.

August 9, 2011

The company has partnered with Teva Pharmaceutical Industries of Israel to develop Multikine.

Cel-Sci Corporation (NYSE AMEX: CVM)with headquarters in Vienna, Va.,posted a net loss for Q2 2011, nearly six times deeper than in the second quarter of 2010.

Losses were $3.11 Million in the three-months quarter ended June 30, 2011 compared to $601,124 in 2010.

Revenue in the second quarter came entirely from grants and totaled a small sum of $77,403.

The company's expenses grew to $4.85 Million from $3.4 Million.

August 9, 2011

Stella went into the hospital with a pain so great it cripples her entire being.  “It feels like a stabbing needle pain that shoots through my joints” she said.  No longer able to carry on her day to day routine she finally gives in after a few pills of over-the-counter pain medication did not work, and heads to the emergency room.  Her body is used to taking high doses of pain medication to alleviate the pain, so no regular pill will work.  The doctors and nurses in the hospital are too familiar with the patient; the only

August 8, 2011

Human Genome Sciences  wants to make sure it's ready for a multi-billion dollar global market

Fresh off an approval of Benlysta by the European Commission (EC) to sell the first Lupus drug in 56 years— Human Genome Sciences (NASDAQ: HGSI) next strategy is to make sure they can meet projected worldwide demand that could soar to revenues as high as $6 Billion annually.

August 14, 2015

Fresh off winning a $20 million Ebola treatment contract from the Department of Health and Human Services, Gaithersburg, Md.-based Emergent BioSolutions (NYSE: EBS) has been awarded another contract, this time from Centers for Disease Control and Prevention (CDC).

The biodefense company announced that the CDC has exercised an option to increase its supply of Vaccinia Immune Globulin (VIGIV), a smallpox vaccine.

July 31, 2015

The Gaithersburg, Md.-based biotech that came up with a faster and innovative way to produce vaccines has announced positive data from a Phase 2 trial focused on developing an Influenza vaccine.

July 30, 2015

Bethesda-based Lockheed Martin and Montgomery College are teaming up create healthcare technologies covering wide range of health related areas from national-scale genomics to big data.

The launch of the Healthcare Technology Alliance could help grow the Health Information Technology sector in Montgomery County as well as form synergies between established industries like biotechnology and promising ones like cyber security.

In addition to Lockheed Martin and Montgomery College, the founding members of the alliance include Cisco, Cloudera, Illumina, Intel.

July 20, 2015

Biodefense company Emergent BioSolutions (NYSE: EBS) won a large Biomedical Advanced Research and Development Authority (BARDA) contract to treat Ebola Monoclona.

The contract is the company's first BARDA Task Order to create an Ebola treatment under the Center for Innovation in Advanced Development and Manufacturing (CIADM) program. BARDA is an authority under the U.S. Department of Health and Human Services.

July 14, 2015

Germantown, Md-based Qiagen Sciences (NASDAQ: QGEN) has received Food and Drug Adminstration approval to market it's therascreen EGFR testing kit in the United States.

June 23, 2015

Gaithersburg-based GlycoMimetics (soon to be in North Rockville) received a another large payment from Pfizer.

GlycoMimetics (NASDAQ: GLYC) has entered its Phase 3 clinical trial called RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) to treat people with sickle cell disease who are six years of age or older.

March 21, 2014

Washington, D.C.-based Vanda Pharmaceuticals Inc (NASDAQ:VNDA), has launched a couple of drugs and even recently put into place a television ad campaign. The company is now in need of extra space and will expand into an additional 8,600 square feet at its D.C. headquarters located at 2200 Pennsylvania Avenue.

Vanda will pay the landlord, Square 54 Office Owner LLC, and additional $381,000 for a 12 year and one month term lease beginning on September 1, 2014, although Vanda will get a nine month grace period.

March 13, 2014

In late 2012 Sucampo Pharmaceuticals (NASDAQ: SCMP) received approval from the Food and Drug Administration (FDA)  to expand upon its gastrointestinal drug -- AMITIZA -- to treat people with opioid-induced constipation (OIC) in the United States.

With increasing competition from other biotechnology companies, that approval is keeping the Bethesda-based drug developer ahead of them and profitable, with a net income posted in 3 out of the last 4 quarters of 2013, including the most recent fourth quarter.

March 13, 2014

Germantown, Maryland-based Intrexon Corporation (NYSE:XON) stock was recently upgraded by EVA Dimensions last week but that doesn’t explain yesterdays price surge of more than 10 percent for the company.

Intrexon was the third most price-trending stock on Google Finance yesterday, the stock price of the company increased more than 11.46 percent (+ $3.14) to close at $30.55 per share.

A few reasons that could have driven Intrexon’s stock price higher,

March 13, 2014

In late 2012 Sucampo Pharmaceuticals (NASDAQ: SCMP) received approval from the Food and Drug Administration (FDA)  to expand upon its gastrointestinal drug -- AMITIZA -- to treat people with opioid-induced constipation (OIC) in the United States.

With increasing competition from other biotechnology companies, that approval is keeping the Bethesda-based drug developer ahead of them and profitable, with a net income posted in 3 out of the last 4 quarters of 2013, including the most recent fourth quarter.

March 6, 2014

Silver Spring-based United Therapeutics (NASDAQ: UTHR) finished off 2013 with a strong showing, collecting revenues of over $1.1 billion for the first time in its corporate history as well posting a net profit for the full-year 2013 and upbeat 2014 outlook.

February 28, 2014

Silver Spring, Maryland-based United Therapeutics Corporation (NASDAQ:UTHR) crossed well over $1 billion in revenue for the first time in its corporate history and according to CEO Martine Rothblatt J.D., Ph.D., 2014 will be an even better year.

February 28, 2014

Shareholders of Gaithersburg, Maryland-based GlycoMimetics Inc (NASDAQ:GLYC) are already enjoying 42 percent gains after the company went public in January. The stock started off at $8 per share and has climbed to a high of $13.37, achieved only yesterday.

There’s some speculation as to why the stock price jumped 21 percent on February 25th, rumors range from short interest to major news on the way.

December 16, 2011

The next time you go under the knife, or a soldier returns home after being wounded in action, you might want to thank SimQuest – a company behind a variety of medical training simulations and software solutions custom-designed for their clients. Founded in 2001 by renowned surgeon Howard Champion, MD, SimQuest has three product lines – simulation, gaming and training, and trauma data analysis.

November 28, 2011

Rockville-based, Micromet, Inc. (NASDAQ: MITI), has started the phase 2 trial of its lymphoblastic leukemia drug, blinatumomab (MT103). Blinatumomab utilizes the body’s T cells to kill cancer cells; it is classified as a new group of agents called BiTE® antibodies.

The drug is targeting adult patients with relapsed B-precursor acute lymphoblastic leukemia or (ALL).